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Abstract
Background: Receptor activity modifying protein 1(RAMP1) is a key receptor subunit of calcitonin gene related
peptide (CGRP) playing a critical role in migraine. But variations in RAMP1 gene have not been found to link with
migraine. Still it is elusive that DNA methylation at RAMP1 promoter is associated with migraine.
Methods: A total of 51 blood DNA samples from 26 patients with migraine and 25 matched healthy controls were
collected, extracted and treated with bisulfate. Subsequently DNA methylation levels at RAMP1 promoter region
were measured using Sequenom Mass ARRAY systems.
Results: Among 13 detected CpG sites or units at RAMP1 promoter region, there were no significant differences
between the migraine and control groups, but indicating a low methylation trend overall in migraine group (total
average methylation level: 8.41 % ±1.92 % vs. 9.90 % ± 3.88 %, p = 0.197). Stratification analysis showed that
methylation level at (+25, +27, +31, related to the transcription start site) CpG unit was higher in migraineurs with
migraine family history compared to those without (13.92 % ± 5.97 % vs. 8.77 % ± 6.61 %, p = 0.034), and methylation
level at (+89, +94, +96) CpG unit was lower in migraine female than that in healthy female (2.18 % ± 1.91 % vs. 5.85 %
± 5.41 %, p = 0.02). For female with methylation level at (+89, +94, +96) CpG unit below 3.50 %, the probability of
being a migraine patient was significantly higher than those with methylation level above the threshold (OR: 7.313;
95%CI: 1.439-37.164).
Conclusions: This study provides the first evidence that DNA methylation at RAMP1 promoter might play a role in
migraine. A low methylation trend overall was presented in migraine subjects, and two CpG units were observed to
link with positive migraine family history and female migraine, respectively. Lower methlytion level at (+89, +94, +96)
CpG unit may be a risk of migraine in females.
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Background
Migraine is a common primary headache disorder ranked
as the 7th disabling condition by WHO [1], which affects
approximately 9.3 % population in China [2]. Although
more current advances in migraine have been obtained,
the complex mechanism of migraine is far from fully
understood and it is still lacking biomarkers available for
prediction of migraine susceptibility, differential diagnosis
and the prediction of response to treatment [3].
Epigenetic processes are thought to contribute to the
etiology of many diseases including cancer and vascular
disease, which are mediated through interfering potential
transcription and gene expression [4, 5]. DNA methyla-
tion, a basic epigenetic modulation, mainly occurs at
cytosine residues in the CpG dinucleotides within pro-
moter region, resulting in chromatin compaction and
gene silencing [6]. Also epigenetic alterations have pro-
vided a potential cancer marker, which could be used for
the early examination as well as prediction of thera-
peutic responses [7]. Numerous studies from animal
experiment suggest that DNA methylation accounts for
chronic pain [8]. Epigenetic modulations are supposed
to participate in etiology of migraine, but few clinical
evidence suggest that DNA methylation modulation is
involved in migraine [9].
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Receptor activity modifying protein 1 (RAMP1) is a key
receptor subunit of calcitonin gene related peptide (CGRP),
which functions as an important neural transmitter impli-
cated in migraine [10]. Emerging evidence indicated that
changes in the expression of RAMP1 can affect the sensi-
tivity of cell to CGRP [11]. The Nestin/RAMP1 transgenic
mice, over-expressed human RAMP1 in central neuro-
logical system (CNS), can mimic some features of migraine,
such as photophobia and allodynia, when intracerebroentri-
cular administration of CGRP [12, 13]. These suggested
RAMP1 would have a potential role in migraine. However,
genetic polymorphism studies and genome-wide associated
studies failed to link migraine with variations in RAMP1
gene [14, 15]. Although at the promoter region of RAMP1,
these sequences contain a number of CpG dinucleotides,
few attempts are to investigate the relationship between
DNA methylation of RAMP1 gene and migraine.
In this study, our aim is to explore whether methyla-
tion pattern at the promoter region of RAMP1 gene in




Patients with migraine were recruited at International
Headache Center of Chinese PLA General Hospital from
June to November in 2014. Matched healthy controls were
enrolled from hospital staff and non-consanguineous rela-
tives of patients. All participants had signed informed con-
sents according to the Ethics Committee of PLA General
Hospital.
Patients were inquired medical history and underwent a
detailed physical and neurological examination, as well as
screening head magnetic resonance imaging or computed
tomography. A detailed information of each participants
were recorded including demographic characteristic,
headache features [pain severity (visual analog scale, VAS),
duration of headache and accompanied symptoms during
attacks], family history and medication for treatment. In-
clusion criteria for migraineurs were: (i)definite migraine
with aura or without aura were diagnosed according with
International Classification of Headache Disorders, 3rd
edition (beta version) [16]; (ii)no systematic disease and
not using preventative medicine; and (iii)exclude pregnant
or breast-feeding women. Healthy controls had no head-
ache history and systematic disease.
Blood sample collection and DNA isolation
For all participants, EDTA blood samples were drawn
from the cubital vein and stored at −80 °C until analysis.
Blood DNA were extracted by standard protocols, quan-
tified by NanoDrop 2000(Thermo Scientific, USA). Each
DNA sample was aliquoted and stored at −20 °C for fur-
ther methylation analysis.
DNA methylation analysis with sequenom mass ARRAY
systems
CpG islands of the RAMP1 gene (NC_000002.12) were
analyzed in a 3000 bp region, which comprised putative
promoter sequences and the first exon (−2000 bp to
1000 bp, related to the transcription start site, TSS) using
CpG Island Searcher (http://cpgislands.USC.edu). The pri-
mer was designed by Sequenom EpiDesigner (Sequenom,
San Diego, CA). Production of 505 bp contains the region
(−300 to 205, related to TSS).
Quantitative methylation was analyzed in BGI TECH SO-
LUTIONS (LIUHE BEIJING) Co. Ltd in Beijing, China.
500 ng DNA sample was treated with bisulfate using the
EZ DNA Methylation Gold kit (ZYMO RESEARCH
CORP., Irvine, CA, USA) according to the manufacturer’s
instructions. After bisulfate conversion, PCR amplification
of the CpG islands region was performed: 94 °C, 4 min;
45 cycles of 94 °C, 20 s, 56 °C,30 s, 72 °C, 1 min; then 72 °
C,3 min. For the interested CpG islands, primers were: for-
ward primer 5’-GGGATTTTTGGATTTATTTATTTAGG-
3’, reverse primer 5’-TTAACCTTTTACAAAACAAA-
CACCA-3’. A T7 promoter tag (CAGTAATACGACT-
CACTATAGGGAGAAGGCT) was added to the reverse
primer. Followed treatment with shrimp alkaline phosphat-
ase, T7 polymerase/ribonuclease A and desalting, PCR pro-
duction was conducted with Mass ARRAY EpiTYPER
system (Sequenom, CA, USA) according to manufacturer’s
instructions. Fully methylated DNA and water were as a
positive and negative control, respectively. Percentage of
methylation of each CpG unit or single CpG site was calcu-
lated using EpiTYPER software version 1.0.
Statistical analysis
Normality distribution of variables was examined using
Kolmogorov-Smirnov test. The group differences of
age and gender were compared by independent T test
and exact x2 test, respectively. The non-parametric
Mann–Whitney test was performed to evaluated group
differences with regard to DNA methylation level.
Since the CpG sites within RAMP1 gene promoter re-
gion are not independent but correlated with each
other [17], and the sample size was small, we did not
perform the strict Bonferroni correction or other
conservative approach. The receiver operating charac-
teristic (ROC) curve and Youden criterion were used
to determine the optimal cut-off point of methylation
level. Odds ratio (OR) and 95 % confidence interval
(CI) were computed to estimate the risk factor. In
addition, correlations between average methylation
level and age, VAS scores, as well as migraine duration
were examined by Pearson test. P < 0.05 was set as stat-
istical significance.
All analyses were conducted with SPSS for Windows
(version 20.0, Chicago, IL, USA).
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Results
Subjects demographics
A total of 26 patients with migraine (male: 9, female: 17)
and 25 healthy volunteers (male: 11, female: 14), ranging
from 14 to 58 years old, were recruited. Of 26 migraineurs,
13 had family history of headache and 13 were accompan-
ied photophobia during attacks. The characteristics of
participants are presented in Table 1. There were no signifi-
cant differences in gender and age between migraine and
control groups.
Methylation patterns
Overall, there was no significant difference in the DNA
methylation level among 13 detected CpG sites or units
at the RAMP1 promoter region between migraine and
control groups. Nevertheless, the results only indicated a
low methylation trend in migraine versus control group
(total average methylation level: 8.41 % ±1.92 % vs.
9.90 % ± 3.88 %, p = 0.197).
Further stratification analysis showed that methylation
level at (+25, +27, +31, related to TSS) CpG unit was
higher in migrianeurs with migraine family history than
those without migraine family history (13.92 % ± 5.97 %
vs. 8.77 % ± 6.61 %, p = 0.034) (Fig. 1a).
Interestingly, we found that methylation level at (+89,
+94, +96) CpG unit was significantly lower in migraine
female patients than that in healthy female volunteers
(2.18 % ± 1.91 % vs. 5.85 % ± 5.41 %, p = 0.02) (Fig. 1b),
but not among male participants. To evaluate the
migraine risk of female, 3.50 % methylation level at (+89,
+94, +96) CpG unit as an optimal threshold was
achieved according to ROC and Youden index, display-
ing sensitivity 0.765 and specificity 0.692. For female
with methylation level below 3.50 %, the probability of
being a migraine patient was significantly higher than
those with methylation level above the threshold (OR:
7.313; 95%CI: 1.439-37.164).
Stratification analysis by photophobia was performed
among migraineurs. Differences in methylation pattern
were not observed between photophobia and non-
photophobia group. Furthermore, no significant correl-
ation was found between age within all participants and
average methylation level. Yet, VAS score and duration
of migraineurs were not related with average methyla-
tion level.
Discussion
RAMP1 is a single-transmembrane receptor subunit,
conferring ligand specificity, necessary for the function
of CGRP [18, 19]. Clinical observations reveal that injec-
tion of CGRP could introduce a delayed migraine-like
headache in migraineurs, but not in migraine-free con-
trols [20], which indicates the regulation of RAMP1 gene
could been implicated in migraine susceptibility. Several
transgenic and expression studies also demonstrate that
RAMP1 is involved in migraine [12, 21, 22]. However,
previous genetic variant and genome-wide associated
studies did not show any positive correlation between
RAMP1 and migraine [14, 15]. The underlying mechan-
ism is still unkown. Epigenetic modifications have been
proved to play a crucial role in complex chronic disor-
ders [23, 24]. We hypothesized that epigenetic modula-
tion could participate in the pathological mechanism of
migraine, and expected that differential DNA methyla-
tion of RAMP1 in leukocytes could provide potential
epigenetic biomarkers for the identification and diagno-
sis of migraine.
However, our results showed that no significant differ-
ence of methylation of each examined CpG unit or site
within the region (−300 to 205) was observed between
patients with migraine and healthy controls except for a
low average methylation trend in migraine group. Fur-
thermore, due to animal experiments revealing a link
between overexpression of hu-RAMP1 and photophobia
[13], we are sought to discover the differences of methy-
lation pattern. Unfortunately, we found no statistical
difference between photophobia and non-photophobia
subgroups. Because it is, to our knowledge, the first time
to investigate the methyaltion pattern of RAMP1 in
migraine, we could not perform an accurate power
calculation. Taking account of the small size of samples,
future studies with a larger cohort to increase the power
to obtain significant correlation are required.
Most importantly, we found that (+25, +27, +31) CpG
unit and (+89, +94, +96) CpG unit were associated with
positive migraine family history and female migraine, re-
spectively. When methlytion level of (+89, +94, +96) CpG
unit decreased, the risk of migraine in females seemed
increased, but not in male. Therefore, it is being thought
whether this could be regarded as an epigenetic biomarker
to predict female migraine risk, analogous to tag SNPs,
needs enlarged-size samples to be warranted. Being lack
of the exact mechanism of DNA methylation implicated
in migraine, from the present data, it is difficult to




Age(mean ± SD,years) 35.0 ± 6.9 31.8 ± 7.0
Gender M/F 9/17 11/14
With aura 5
With migraine family history 13
With photophia 13
Duration of migraine (mean ± SD, years) 12.69 ± 8.85
VAS score (mean ± SD) 7.08 ± 1.82
F female; M male, VAS visual analog scale
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interpret the differences of DNA methylation at RAMP1
gene promoter within migraine subgroups. Sex-specific
difference in mRNA levels of RAMP1 have been observed
in rat migraine model [25], as also have been found in the
light-aversion behavior in transgenic hu-RAMP1 mice
[26]. Moreover, recent methylome study also reveals more
genes with sex differences in DNA methylation [27].
Whether female predominance of migraine is associated
with sex-biased methylation, remains to be elucidated.
Finally, we acknowledged that methylation pattern in per-
ipheral leukocyte could not really represent the similar
trend among the tissues of CNS, owing to tissue-specificity
in DNA methylation [17]. Nevertheless, several studies have
suggested that peripherally epigenetic changes could be
used as markers for research purpose in many CNS disor-
ders [28–30]. Zill P and his colleagues analyzed the DNA
methylation pattern of ACE gene in peripheral leukocytes
and found that aberration of DNA methylation at ACE
promoter may be an underlying cause of major depression
[29]. In addition, methylation status of repetitive elements
in blood of Alzheimer’s disease may be novel markers for
risk stratification [28]. These studies further support that
disease-specific DNA methylation changes may occur in
peripheral blood and provide a specific profile of disease.
There were several limitations to be considered. First,
based on the limited samples of the selected population
in our present study, our findings and subsequent con-
clusions need to be further warranted. Second, owing to
undetecting the expression of RAMP1 in the leukocytes,
it is difficult to assess whether and what extent of
methylation level affect the expression of RAMP1. Third,
because of obvious difficulties in obtaining the specific
tissue derived from trigeminovascular or cerebral biop-
sies, we cannot provide direct evidence that epigenetic
modulation is involved in migraine. Finally, peripheral
blood DNA is derived from multiple cell lineages. There-
fore the differences in numbers of subpopulation might
result in distinct DNA methylation patterns.
Conclusions
This study provides the first evidence that DNA methyla-
tion at RAMP1 promoter might play a role in migraine.
Even though we found no significant differences of DNA
methylation pattern between migraine patients and healthy
controls, a low methylation trend overall was presented in
migraine group, and two CpG units were observed to link
with positive migraine family history and female migraine,
respectively. The methylated marker might be helpful to
predict the migraine risk. Still, the results need larger
samples to be further validated and the molecular mechan-
ism underlying remains to be investigated.
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